Edition:
India

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

4.61USD
21 Aug 2019
Change (% chg)

$0.08 (+1.77%)
Prev Close
$4.53
Open
$4.60
Day's High
$4.69
Day's Low
$4.47
Volume
624,447
Avg. Vol
715,453
52-wk High
$36.55
52-wk Low
$3.86

About

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and... (more)

Overall

Beta: 2.22
Market Cap(Mil.): $555.69
Shares Outstanding(Mil.): 83.81
Dividend: --
Yield (%): --

Financials

  MNK.N Industry Sector
P/E (TTM): -- 29.73 33.85
EPS (TTM): -41.47 -- --
ROI: -28.64 13.04 12.69
ROE: -72.61 14.12 17.13

Mallinckrodt shares fall on Acthar worries, generics spinoff suspension

Mallinckrodt Plc suspended plans to spin off its specialty generics unit, citing opioid litigation uncertainties, and warned Acthar gel revenue was unlikely to exceed $1 billion this year, sending its shares down about 15% on Tuesday.

06 Aug 2019

UPDATE 4-Mallinckrodt shares fall on Acthar worries, generics spinoff suspension

Aug 6 Mallinckrodt Plc suspended plans to spin off its specialty generics unit, citing opioid litigation uncertainties, and warned Acthar gel revenue was unlikely to exceed $1 billion this year, sending its shares down about 15% on Tuesday.

06 Aug 2019

Mallinckrodt suspends plans to spin off generics unit

Aug 6 Mallinckrodt Plc said on Tuesday it has suspended plans to spin off its specialty generics business, citing uncertainties tied to the opioid litigation and current market conditions.

06 Aug 2019

Mallinckrodt to settle U.S. drug marketing probe, fight kickback case

Mallinckrodt Plc on Wednesday said it had tentatively agreed to pay $15.4 million to resolve a U.S. Justice Department probe into how a drugmaker it now owns marketed an expensive treatment for a rare infant seizure disorder and multiple sclerosis.

05 Jun 2019

UPDATE 1-Mallinckrodt to settle U.S. drug marketing probe, fight kickback case

June 5 Mallinckrodt Plc on Wednesday said it had tentatively agreed to pay $15.4 million to resolve a U.S. Justice Department probe into how a drugmaker it now owns marketed an expensive treatment for a rare infant seizure disorder and multiple sclerosis.

05 Jun 2019

Mallinckrodt expects to pay DoJ $15.4 mln over Questcor investigation

June 5 Mallinckrodt Plc said on Wednesday it reached an agreement with the U.S. Department of Justice to resolve a government investigation into its subsidiary Questcor and expects to pay $15.4 million.

05 Jun 2019

Mallinckrodt's Amitiza to stay with branded business after spin-off

Mallinckrodt Plc said on Tuesday it would spin off its generic drugs business as a separate unit and keep constipation medicine Amitiza as part of its specialty branded drugs business, which will be renamed as Sonorant Therapeutics Plc.

28 May 2019

UPDATE 2-Mallinckrodt's Amitiza to stay with branded business after spin-off

May 28 Mallinckrodt Plc said on Tuesday it would spin off its generic drugs business as a separate unit and keep constipation medicine Amitiza as part of its specialty branded drugs business, which will be renamed as Sonorant Therapeutics Plc.

28 May 2019

Mallinckrodt to spin-off generics business, keep constipation drug

May 28 Mallinckrodt Plc said on Tuesday it would spin-off its specialty generics unit and rename the remaining specialty branded drugs business to Sonorant Therapeutics Plc.

28 May 2019

Mallinckrodt sues U.S. health agencies, sees 10% hit to Acthar gel sales

Mallinckrodt Plc filed a lawsuit against the U.S. Department of Health and Human Services and forecast an about 10% hit to annual net sales of Acthar gel following changes to Medicaid rebate calculations, sending its shares plunging as much as 34% on Tuesday.

21 May 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates